Pacific Biosciences Of California, Inc. (PACB): who owns it and who trades it
As of Nov 16, 2026, PACB insiders reported 12 open-market sales worth $3.4M and no purchases in the last 12 months, with 61% of the sale value made under pre-set 10b5-1 plans. The largest seller was James R Gibson II (See Remarks), with $2.2M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Pacific Biosciences Of California
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, PACB insiders reported $0 of open-market purchases and $3.4M of sales. 61% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | James R Gibson II | See Remarks | Sale plan | 661,815 | $3.11 | $2.1M | Form 4 |
| Aug 17, 2026 | Oene Mark Van | See Remarks | Sale | 26,911 | $1.13 | $30.4K | Form 4 |
| Apr 1, 2026 | James R Gibson II | See Remarks | Sale | 88,185 | $1.37 | $121K | Form 4 |
| Mar 3, 2026 | Christian O Henry | See Remarks | Sale | 12,497 | $1.51 | $18.9K | Form 4 |
| Mar 3, 2026 | Oene Mark Van | See Remarks | Sale | 6,504 | $1.51 | $9.8K | Form 4 |
| Mar 3, 2026 | Michele Farmer | See Remarks | Sale | 2,979 | $1.51 | $4.5K | Form 4 |
| Feb 18, 2026 | Oene Mark Van | See Remarks | Sale | 55,107 | $1.63 | $89.8K | Form 4 |
| Feb 18, 2026 | Christian O Henry | See Remarks | Sale | 140,874 | $1.63 | $230K | Form 4 |
| Feb 18, 2026 | Michele Farmer | See Remarks | Sale | 14,952 | $1.63 | $24.4K | Form 4 |
| Feb 17, 2026 | Oene Mark Van | See Remarks | Sale | 129,790 | $1.58 | $205K | Form 4 |
| Feb 17, 2026 | Christian O Henry | See Remarks | Sale | 331,793 | $1.58 | $524K | Form 4 |
| Feb 17, 2026 | Michele Farmer | See Remarks | Sale | 35,215 | $1.58 | $55.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| James R Gibson II | See Remarks | – | $2.2M | Oct 6, 2026 |
| Christian O Henry | See Remarks | – | $773K | Mar 3, 2026 |
| Oene Mark Van | See Remarks | – | $335K | Aug 17, 2026 |
| Michele Farmer | See Remarks | – | $84.5K | Mar 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PACB short interest
High short interest. 17.3% of PACB shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 10%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 53.68M PACB shares were sold short, 17.3% of the shares outstanding, up 14.4% from the report before. At the average daily volume of 12.98M shares, buying them all back would take about 4.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 53.68M | 17.27% | +14% | 12.98M | 4.1 |
| Oct 15, 2026 | 46.93M | 15.10% | -1% | 21.42M | 2.2 |
| Sep 30, 2026 | 47.22M | 15.19% | -3% | 15.91M | 3.0 |
| Sep 15, 2026 | 48.89M | 15.73% | -1% | 4.66M | 10.5 |
| Aug 31, 2026 | 49.58M | 15.95% | -7% | 7.34M | 6.8 |
| Aug 14, 2026 | 53.41M | 17.18% | +9% | 8.06M | 6.6 |
| Jul 31, 2026 | 49.00M | 15.77% | +6% | 6.67M | 7.3 |
| Jul 15, 2026 | 46.24M | 14.89% | -3% | 4.64M | 10.0 |
| Jun 30, 2026 | 47.49M | 15.29% | -22% | 7.29M | 6.5 |
| Jun 15, 2026 | 60.56M | 19.50% | +24% | 5.95M | 10.2 |
| May 29, 2026 | 48.71M | 15.68% | -19% | 5.68M | 8.6 |
| May 15, 2026 | 59.93M | 19.29% | +27% | 6.65M | 9.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Pacific Biosciences Of California company events
Pacific Biosciences Of California filed 12 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026AgreementPacific Biosciences of California, Inc. entered into a Sales Agreement with Allen & Company LLC to sell shares of the Company’s common stock, par value $0.001 per share, having aggregate sales proceeds of up to $100 million, from time to time, through an “at-the-market” equity offering program… Filing
- Nov 4, 2026LeadershipJim Gibson stepped down as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company and transitioned to a non-executive advisory role[ as an advisor to the Chief Executive Officer]. Mr. Gibson is expected to remain employed by the Company in that… Filing
- Aug 5, 2026LeadershipThe Board appointed Mark Van Oene, age 54, as the Company’s President and Chief Executive Officer and as a member of the Board, effective August 5, 2026. Filing
- Jul 9, 2026LeadershipChristopher M. Smith, a member of the board of directors of Pacific Biosciences of California, Inc., notified the Company of his resignation from the Board, effective immediately. Filing
- Jun 4, 2026LeadershipThe board of directors of Pacific Biosciences of California, Inc., at the recommendation of the compensation committee of the Board, approved an amendment to the Company’s 2020 Equity Incentive Plan, subject to stockholder approval, to reserve an additional 16,000,000 shares of the Company’s common… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 6, 2026LeadershipMichele Farmer notified Pacific Biosciences of California, Inc. that she is voluntarily resigning as Chief Accounting Officer of the Company effective on March 21, 2026, to pursue another opportunity. Filing
- Mar 5, 2026LeadershipThe Board of Directors of Pacific Biosciences of California, Inc., upon the recommendation of its Corporate Governance and Nominating Committee, increased the size of the Board to ten directors and appointed Christopher Gibson, Ph.D. to serve as a Class I director effective as of the Effective… Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Feb 3, 2026LeadershipPacific Biosciences of California, Inc. announced that, effective January 28, 2026, Mark Van Oene, the Company’s Chief Operating Officer, will on an interim basis assume responsibilities for the Company’s sales and customer support organizations, which were previously assigned to Christian Henry… Filing
- Feb 2, 2026DealBelow is hereby incorporated by reference into this Item 1.01. Filing
- Jan 12, 2026AnnouncementThe information set forth in the Press Release, solely to the extent such information references the Company’s expectations for preliminary revenue estimates for the quarter and year ended December 31, 2025 and preliminary cash, cash equivalents and investments balance as of December 31, 2025… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Pacific Biosciences Of California financials
Famous investors that hold PACB
6 of the 50 well-known investors we track reported holding PACB in their latest 13F filing. The largest position is Cathie Wood's, worth $70.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 29.75M | $70.5M | 0.4% | -0% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 6.52M | $15.4M | 0.0% | +129% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 5.59M | $13.2M | 0.0% | +17% |
| Israel Englander · Millennium Management | Q3 2026 | 3.75M | $8.9M | 0.0% | -5% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 684,707 | $1.6M | 0.0% | No change |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 69,747 | $165K | 0.0% | -32% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PACB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G | 7.6% |
| Nov 9, 2026 | THE GOLDMAN SACHS GROUP, INC. | 13G | 7.6% |
| Nov 6, 2026 | T. Rowe Price Associates, Inc. | 13G | 10.8% |
| Nov 6, 2026 | T. Rowe Price Associates, Inc. | 13G | 10.8% |
Questions about Pacific Biosciences Of California, Inc. (PACB) stock
Are PACB insiders buying or selling?
In the last 12 months, PACB insiders reported no open-market purchases and 12 sales worth $3.4M. The latest trade was on Oct 6, 2026. See every trade.
What is the short interest in PACB?
As of Oct 30, 2026, 53.68M PACB shares were sold short, 17.3% of the shares outstanding, up 14.4% from the report before. At the average daily volume of 12.98M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.
Which famous investors hold PACB?
6 of the 50 well-known investors we track reported PACB in their latest 13F filing, including Cathie Wood, Ken Griffin, Steve Cohen. The largest position is worth $70.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.